

Mihai Gheorghiu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8672586/mihai-gheorghiu-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

149
papers

13,155
citations

48
h-index

113
g-index

169
ext. papers

15,512
ext. citations

8.3
avg, IF

6.14
L-index

#	Paper	IF	Citations
149	Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial. <i>Clinical Pharmacology in Drug Development</i> , 2019 , 8, 942-951	2.3	10
148	Assessment and management of coronary artery disease in kidney and pancreas transplant candidates. <i>Journal of Cardiovascular Medicine</i> , 2019 , 20, 51-58	1.9	6
147	Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. <i>European Journal of Heart Failure</i> , 2019 , 21, 286-296	12.3	32
146	Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure?. <i>Journal of Cardiac Failure</i> , 2018 , 24, 112-114	3.3	6
145	Expanded algorithm for managing patients with acute decompensated heart failure. <i>Heart Failure Reviews</i> , 2018 , 23, 597-607	5	4
144	Lessons learned in acute heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 630-641	12.3	19
143	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 281-291	12.3	17
142	Past, present, and future of acute heart failure clinical trials-a high-risk population in search of a strategy. <i>European Journal of Heart Failure</i> , 2018 , 20, 839-841	12.3	3
141	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2018 , 122, 255-260	3	4
140	Mobile health applications in cardiovascular research. <i>International Journal of Cardiology</i> , 2018 , 269, 265-271	3.2	13
139	Acute Dyspnea and Decompensated Heart Failure. <i>Cardiology Clinics</i> , 2018 , 36, 63-72	2.5	8
138	Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 677-686	12.3	13
137	A new educational program in heart failure drug development: the Brescia international master program. <i>Journal of Cardiovascular Medicine</i> , 2018 , 19, 411-421	1.9	7
136	A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. <i>Journal of Cardiac Failure</i> , 2018 , 24, 783-792	3.3	6
135	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 1501-1510	12.3	20
134	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , 2017 , 230, 301-303	3.2	5
133	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 556-569	15.1	135

132	Is there a clinically meaningful difference in patient reported dyspnea in acute heart failure? An analysis from URGENT Dyspnea. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2017 , 46, 300-307	2.6	8
131	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2017 , 19, 552-562	12.3	19
130	Patient-reported outcomes in the SOLuble guanylate Cyclase stimulator in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. <i>European Journal of Heart Failure</i> , 2017 , 19, 782-791	12.3	54
129	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , 2017 , 38, 1119-1127	9.5	192
128	Redefining the role of biomarkers in heart failure trials: expert consensus document. <i>Heart Failure Reviews</i> , 2017 , 22, 263-277	5	13
127	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 768-776	3.8	8
126	Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	11
125	Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. <i>Nature Reviews Cardiology</i> , 2017 , 14, 238-250	14.8	322
124	Partial Adenosine A1 Agonist in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2017 , 243, 177-203	3.3	19
123	Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2017 , 4, 402-408	3.7	32
122	Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. <i>International Journal of Cardiology</i> , 2017 , 248, 414-420	3.2	4
121	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome. <i>JAMA Cardiology</i> , 2017 , 2, 995-1006	16.2	107
120	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	26
119	Regional Validation and Recalibration of Clinical Predictive Models for Patients With Acute Heart Failure. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	13
118	Novel Endpoints for Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , 2017 , 14, 210-216	2.8	7
117	Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. <i>Circulation Research</i> , 2017 , 120, 332-340	15.7	105
116	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 440-451	2.9	33
115	Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. <i>Cardiac Failure Review</i> , 2017 , 3, 122-129	4.2	18

114	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <i>European Heart Journal</i> , 2016 , 37, 2105-14	9.5	184
113	Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. <i>BMC Cardiovascular Disorders</i> , 2016 , 16, 199	2.3	25
112	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	36
111	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2016 , 117, 1144-50	3	16
110	Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. <i>American Journal of Cardiology</i> , 2016 , 117, 1845-50	3	8
109	Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. <i>Heart Failure Reviews</i> , 2016 , 21, 95-102	5	44
108	Trends in Heart Failure Clinical Trials From 2001-2012. <i>Journal of Cardiac Failure</i> , 2016 , 22, 171-9	3.3	13
107	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2016 , 117, 611-616	3	11
106	Utility of positron emission tomography for drug development for heart failure. <i>American Heart Journal</i> , 2016 , 175, 142-52	4.9	7
105	Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. <i>European Journal of Heart Failure</i> , 2016 , 18, 185-91	12.3	7
104	Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. <i>International Journal of Cardiology</i> , 2016 , 214, 16-8	3.2	2
103	In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. <i>JACC: Heart Failure</i> , 2016 , 4, 580-588	7.9	9
102	Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender : Results from the PROBE-HF study. <i>Clinical Research in Cardiology</i> , 2016 , 105, 421-31	6.1	13
101	Hyperkalemia in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1575-89	15.1	60
100	Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	8
99	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <i>European Journal of Heart Failure</i> , 2016 , 18, 54-65	12.3	57
98	Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies. <i>Circulation: Heart Failure</i> , 2015 , 8, 826-31	7.6	28
97	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. <i>American Journal of Cardiology</i> , 2015 , 116, 1304-10	3	3

96	Trends in characteristics of cardiovascular clinical trials 2001-2012. <i>American Heart Journal</i> , 2015 , 170, 263-72	4.9	23
95	Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. <i>European Journal of Heart Failure</i> , 2015 ,	12.3	56
94	Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015 , 169, 305-14	4.9	18
93	Digoxin use in atrial fibrillation: a critical reappraisal. <i>Lancet, The</i> , 2015 , 385, 2330-2	4.0	10
92	Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2038-2047	15.1	40
91	"Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2015 , 3, 661-9	7.9	28
90	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2251-62	27.4	188
89	Roadmap to inpatient heart failure management. <i>Journal of Cardiology</i> , 2015 , 65, 26-31	3	3
88	Phenomapping for novel classification of heart failure with preserved ejection fraction. <i>Circulation</i> , 2015 , 131, 269-79	16.7	499
87	Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2015 , 17, 591-600	12.3	52
86	Letter by Abu Daya et al Regarding Article, "Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction, Contributions of Collagen and Titin". <i>Circulation</i> , 2015 , 132, e248	16.7	
85	Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. <i>European Journal of Heart Failure</i> , 2015 , 17, 760-3	12.3	14
84	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , 2015 , 17, 1104-13	12.3	43
83	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2015 , 17, 1022-31	12.3	40
82	Agents with vasodilator properties in acute heart failure: how to design successful trials. <i>European Journal of Heart Failure</i> , 2015 , 17, 652-64	12.3	24
81	Pulmonary Oedema-Therapeutic Targets. <i>Cardiac Failure Review</i> , 2015 , 1, 38-45	4.2	6
80	Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012). <i>American Journal of Cardiology</i> , 2015 , 116, 307-12	3	2
79	Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). <i>American Journal of Cardiology</i> , 2015 , 115, 790-6 ³		28

78	Population risk prediction models for incident heart failure: a systematic review. <i>Circulation: Heart Failure</i> , 2015 , 8, 438-47	7.6	40
77	Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	119
76	The vulnerable phase after hospitalization for heart failure. <i>Nature Reviews Cardiology</i> , 2015 , 12, 220-9	14.8	129
75	Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. <i>JACC: Heart Failure</i> , 2015 , 3, 136-45	7.9	190
74	Therapeutic targets in heart failure: refocusing on the myocardial interstitium. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2188-98	15.1	90
73	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1123-1133	15.1	1160
72	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. <i>JACC: Heart Failure</i> , 2014 , 2, 97-112	7.9	213
71	The burden of acute heart failure on U.S. emergency departments. <i>JACC: Heart Failure</i> , 2014 , 2, 269-77	7.9	118
70	Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). <i>American Journal of Cardiology</i> , 2014 , 114, 1713-21	3	35
69	Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 401-8	7.6	27
68	Clinical effectiveness of CRT and ICD therapy in heart failure patients by racial/ethnic classification: insights from the IMPROVE HF registry. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 797-807	15.1	23
67	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014 , 35, 2797-815	9.5	231
66	Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014 , 114, 743-50	3	8
65	The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1823-32	15.1	67
64	Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. <i>American Heart Journal</i> , 2014 , 168, 142-9	4.9	25
63	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. <i>Heart Failure Reviews</i> , 2014 , 19, 135-52	5	39
62	Hemoconcentration-guided diuresis in heart failure. <i>American Journal of Medicine</i> , 2014 , 127, 1154-9	2.4	32
61	Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 789-90	27.4	42

60	Molecular and cellular basis of viable dysfunctional myocardium. <i>Circulation: Heart Failure</i> , 2014 , 7, 680-916	35
59	Management of comorbid diabetes mellitus and worsening heart failure. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 2379-80	27.4 39
58	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013 , 18, 107-22	5 39
57	Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2013 , 15, 679-89	12.3 26
56	The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. <i>JACC: Heart Failure</i> , 2013 , 1, 488-96	7.9 49
55	Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 571-8	15.1 47
54	Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives. <i>Heart Failure Clinics</i> , 2013 , 9, 285-90, v-vi	3.3 25
53	Anticoagulation in heart failure: current status and future direction. <i>Heart Failure Reviews</i> , 2013 , 18, 797-813	22
52	Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 1125-35	27.4 248
51	Soluble guanylate cyclase: a potential therapeutic target for heart failure. <i>Heart Failure Reviews</i> , 2013 , 18, 123-34	5 92
50	Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. <i>European Journal of Heart Failure</i> , 2013 , 15, 551-9	12.3 54
49	Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. <i>Congestive Heart Failure</i> , 2012 , 18, 9-17	55
48	A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. <i>Heart Failure Reviews</i> , 2012 , 17, 485-509	5 79
47	Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. <i>European Journal of Heart Failure</i> , 2012 , 14, 1056-66	12.3 88
46	A proposed model for initial assessment and management of acute heart failure syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1702-3	27.4 41
45	Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. <i>American Heart Journal</i> , 2011 , 161, 224-32	4.9 32
44	Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2011 , 30, 218-26	5.8 25
43	Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). <i>European Journal of Heart Failure</i> , 2011 , 13, 100-6	12.3 60

42	Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 2456-7	27.4	28
41	Heart failure in 2010: one step forward, two steps back. <i>Nature Reviews Cardiology</i> , 2011 , 8, 72-3	14.8	6
40	Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output. <i>Discovery Medicine</i> , 2011 , 12, 141-51	2.5	14
39	Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. <i>European Journal of Heart Failure</i> , 2010 , 12, 423-33	12.3	436
38	Digoxin for the treatment of chronic and acute heart failure syndromes. <i>Acute Cardiac Care</i> , 2009 , 11, 83-7		19
37	Reconsidering the role for digoxin in the management of acute heart failure syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 2146-7	27.4	47
36	Response to the Letter of Hester Den Ruijter and Ruben Coronel Regarding the Article [The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy] <i>Cardiovascular Drugs and Therapy</i> , 2009 , 23, 335-336	3.9	
35	Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. <i>American Heart Journal</i> , 2009 , 157, 957-70	4.9	43
34	The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. <i>American Heart Journal</i> , 2009 , 158, 437-43	4.9	13
33	Acute heart failure syndromes. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 557-573	15.1	426
32	Nutritional supplementation with amino acids in cardiovascular and metabolic diseases: hypermetabolic syndrome as a therapeutic target. Introduction. <i>American Journal of Cardiology</i> , 2008 , 101, 1E-2E	3	2
31	Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 2276-85	15.1	113
30	Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. <i>European Heart Journal</i> , 2007 , 28, 980-8	9.5	431
29	Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1332-43	27.4	625
28	Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. <i>Archives of Internal Medicine</i> , 2007 , 167, 1998-2005		252
27	Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. <i>American Journal of Cardiology</i> , 2006 , 97, 1064-7	3	113
26	Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 296, 2217-26	27.4	687
25	Contemporary use of digoxin in the management of cardiovascular disorders. <i>Circulation</i> , 2006 , 113, 2556-64	16.7	143

24	Treatment of congestion in acute heart failure syndromes: importance, strategies, and challenges. Introduction. <i>American Journal of Medicine</i> , 2006 , 119, S1-2	2.4	13
23	Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. <i>American Journal of Medicine</i> , 2006 , 119, S3-S10	2.4	272
22	The clinical effects of vasopressin receptor antagonists in heart failure. <i>Cleveland Clinic Journal of Medicine</i> , 2006 , 73 Suppl 2, S24-9; discussion S30-3	2.8	8
21	Congestion is an important diagnostic and therapeutic target in heart failure. <i>Reviews in Cardiovascular Medicine</i> , 2006 , 7 Suppl 1, S12-24	3.9	10
20	Introduction to acute heart failure syndromes. <i>American Journal of Cardiology</i> , 2005 , 96, 1G-4G	3	21
19	The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). <i>American Journal of Cardiology</i> , 2005 , 96, 18G-25G	3	53
18	Pharmacology of new agents for acute heart failure syndromes. <i>American Journal of Cardiology</i> , 2005 , 96, 68G-73G	3	49
17	The challenge of acute heart failure syndromes. <i>American Journal of Cardiology</i> , 2005 , 96, 86G-9G	3	17
16	Neurohormonal inhibition in heart failure: insights from recent clinical trials. <i>American Journal of Cardiology</i> , 2005 , 96, 3L-9L	3	204
15	Acute heart failure syndromes: current state and framework for future research. <i>Circulation</i> , 2005 , 112, 3958-68	16.7	583
14	Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 291, 1963-71	27.4	511
13	Digoxin in the management of cardiovascular disorders. <i>Circulation</i> , 2004 , 109, 2959-64	16.7	171
12	Closing statement. <i>American Journal of Medicine</i> , 2004 , 116 Suppl 5A, 89S-90S	2.4	
11	Improvement in the function of hibernating myocardium in a patient with heart failure due to coronary artery disease receiving high-dose simvastatin. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2004 , 5, 160-2		2
10	OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization. <i>European Journal of Heart Failure</i> , 2003 , 5, 9-12	12.3	12
9	Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. <i>American Heart Journal</i> , 2003 , 145, S51-4	4.9	37
8	Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). <i>American Heart Journal</i> , 2003 , 145, S55-7	4.9	4
7	Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. <i>American Heart Journal</i> , 2003 , 145, S60-1	4.9	9

6	Surrogate end points in heart failure trials. <i>American Heart Journal</i> , 2003 , 145, S67-70	4.9	16
5	Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. <i>Circulation</i> , 2003 , 107, 2690-6	16.7	369
4	Patterns of angiotensin-converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure. <i>Clinical Cardiology</i> , 1998 , 21, 261-8	3.3	18
3	Chronic heart failure in the United States: a manifestation of coronary artery disease. <i>Circulation</i> , 1998 , 97, 282-9	16.7	640
2	Standards of laboratory practice: cardiac drug monitoring. <i>Clinical Chemistry</i> , 1998 , 44, 1096-1109	5.5	44
1	Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1994 , 8, 761-8	3.9	2